<DOC>
	<DOC>NCT00092547</DOC>
	<brief_summary>This study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).</brief_summary>
	<brief_title>A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)</brief_title>
	<detailed_description>The original base protocol (V501-018)(NCT00092547) was extended in amendments V501-018-05 and -06 to provide 37 months of follow-up. Additionally, subjects in the Placebo Group during the base study were given 3 doses of open-label GARDASILâ„¢ (V501) at Months 30, 32, and 36. The study was extended again in amendment V501-018-10(NCT00092547), titled "A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age" to allow a follow-up period to Month 126.</detailed_description>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adolescents and preadolescents with no prior sexual history Subjects with compromised immune system or have a history of severe allergic reaction</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>